Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Alnylam Pharmaceuticals·Products & Services·1 segment
Breakdown
| Segment | Q1 '26 |
|---|---|
| Zilebesrian | $6.00M |
| Total | $6.00M |
Segments
ZilebesrianView metric
| Segment | Q1 '26 |
|---|---|
| Zilebesrian | $6.00M |
| Total | $6.00M |